315 related articles for article (PubMed ID: 34894403)
1. Immunogenicity after 6 months of BNT162b2 vaccination in frail or disabled nursing home residents: The COVID-A Study.
Salmerón Ríos S; Cortés Zamora EB; Avendaño Céspedes A; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Mas Romero M; Tabernero Sahuquillo MT; Blas Señalada JJ; Murillo Romero A; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Lauschke VM; Stebbing J; Abizanda P
J Am Geriatr Soc; 2022 Mar; 70(3):650-658. PubMed ID: 34894403
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
Salmerón Ríos S; Mas Romero M; Cortés Zamora EB; Tabernero Sahuquillo MT; Romero Rizos L; Sánchez-Jurado PM; Sánchez-Nievas G; Señalada JJB; García Nogueras I; Estrella Cazalla JD; Andrés-Pretel F; Murillo Romero A; Lauschke VM; Stebbing J; Abizanda P
J Am Geriatr Soc; 2021 Jun; 69(6):1441-1447. PubMed ID: 33768521
[TBL] [Abstract][Full Text] [Related]
3. Previous SARS-CoV-2 Infection, Age, and Frailty Are Associated With 6-Month Vaccine-Induced Anti-Spike Antibody Titer in Nursing Home Residents.
Dyer AH; Noonan C; McElheron M; Batten I; Reddy C; Connolly E; Pierpoint R; Murray C; Leonard A; Higgins C; Reilly P; Boran G; Phelan T; McCormack W; O'Neill D; Fallon A; Brady G; O'Farrelly C; Bourke NM; Kennelly SP
J Am Med Dir Assoc; 2022 Mar; 23(3):434-439. PubMed ID: 35219507
[TBL] [Abstract][Full Text] [Related]
4. Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home Residents.
Montejano-Hervás P; Gómez-Pavón J; Tornero-Torres O; Valverde-Moyar MV; Martín Cruz B; Vela Carbonera M; Fuentes-Irigoyen R; Tejada González P; González-Becerra M; Higueras Sánchez E; Ramos Cordero P
Drugs Aging; 2022 Jul; 39(7):587-595. PubMed ID: 35794430
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
6. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection status.
Seiffert P; Konka A; Kasperczyk J; Kawa J; Lejawa M; Maślanka-Seiffert B; Zembala-John J; Bugdol M; Romanik M; Bułdak R; Marcisz C; Derejczyk J; Religa D
Biogerontology; 2022 Feb; 23(1):53-64. PubMed ID: 34923608
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, effectiveness and safety of COVID-19 vaccine in older adults living in nursing homes: A real-life study.
Meijide Míguez H; Montes García I; Ochando Gómez M; García Merino IM; Cano EL; De La Torre A
Rev Esp Geriatr Gerontol; 2023; 58(3):125-133. PubMed ID: 37031072
[TBL] [Abstract][Full Text] [Related]
9. Maternal and Neonatal SARS-CoV-2 Immunoglobulin G Antibody Levels at Delivery After Receipt of the BNT162b2 Messenger RNA COVID-19 Vaccine During the Second Trimester of Pregnancy.
Kugelman N; Nahshon C; Shaked-Mishan P; Cohen N; Sher ML; Gruber M; Marom I; Zolotarevsky A; Lavie O; Damti A; Zilberlicht A; Bardicef M; Kedar R
JAMA Pediatr; 2022 Mar; 176(3):290-295. PubMed ID: 34932066
[TBL] [Abstract][Full Text] [Related]
10. Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents.
Blain H; Tuaillon E; Gamon L; Pisoni A; Miot S; Picot MC
J Am Med Dir Assoc; 2022 May; 23(5):750-753. PubMed ID: 35311651
[TBL] [Abstract][Full Text] [Related]
11. Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
Muhsen K; Maimon N; Mizrahi AY; Varticovschi B; Bodenheimer O; Cohen D; Dagan R
JAMA Netw Open; 2022 Jul; 5(7):e2219940. PubMed ID: 35796153
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
13. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan.
Kageyama T; Ikeda K; Tanaka S; Taniguchi T; Igari H; Onouchi Y; Kaneda A; Matsushita K; Hanaoka H; Nakada TA; Ohtori S; Yoshino I; Matsubara H; Nakayama T; Yokote K; Nakajima H
Clin Microbiol Infect; 2021 Dec; 27(12):1861.e1-1861.e5. PubMed ID: 34375755
[TBL] [Abstract][Full Text] [Related]
14. Early Immunogenicity and Safety of the Third Dose of BNT162b2 Messenger RNA Coronavirus Disease 2019 Vaccine Among Adults Older Than 60 Years: Real-World Experience.
Gilboa M; Mandelboim M; Indenbaum V; Lustig Y; Cohen C; Rahav G; Asraf K; Amit S; Jaber H; Nemet I; Kliker L; Bar-Haim E; Mendelson E; Doolman R; Rubin C; Regev-Yochay G; Kreiss Y
J Infect Dis; 2022 Mar; 225(5):785-792. PubMed ID: 34850049
[TBL] [Abstract][Full Text] [Related]
15. Evolution of antibody titers after two doses of mRNA Pfizer-BioNTech vaccine and effect of the third dose in nursing home residents.
Rodríguez-Avial I; García-Salguero C; Bermejo L; Teja J; Pérez-Cecilia E; Delgado-Iribarren A; Vigara M; Gil P; Culebras E
PLoS One; 2023; 18(3):e0282388. PubMed ID: 36888608
[TBL] [Abstract][Full Text] [Related]
16. T-Cell Mediated Response after Primary and Booster SARS-CoV-2 Messenger RNA Vaccination in Nursing Home Residents.
Schiavoni I; Palmieri A; Olivetta E; Leone P; Di Lonardo A; Mazzoli A; Cafariello C; Malara A; Palamara AT; Incalzi RA; Onder G; Stefanelli P; Fedele G;
J Am Med Dir Assoc; 2023 Feb; 24(2):140-147.e2. PubMed ID: 36587928
[TBL] [Abstract][Full Text] [Related]
17. Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities.
Causa R; Almagro-Nievas D; Rivera-Izquierdo M; Benítez-Muñoz N; López-Hernández B; García-García F; Alvarez-Estévez M; Soto-Pérez MO; Bermúdez-Tamayo C
Gerontology; 2022; 68(8):910-916. PubMed ID: 34758461
[TBL] [Abstract][Full Text] [Related]
18. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents.
Chong Y; Goto T; Tani N; Yonekawa A; Ikematsu H; Shimono N; Tanaka Y; Akashi K
Influenza Other Respir Viruses; 2022 Nov; 16(6):1066-1071. PubMed ID: 35962568
[TBL] [Abstract][Full Text] [Related]
19. Decline in Antibody Concentration 6 Months After Two Doses of SARS-CoV-2 BNT162b2 Vaccine in Solid Organ Transplant Recipients and Healthy Controls.
Hamm SR; Møller DL; Pérez-Alós L; Hansen CB; Pries-Heje MM; Heftdal LD; Hasselbalch RB; Fogh K; Madsen JR; Almagro Armenteros JJ; Knudsen AD; Poulsen JR; Frikke-Schmidt R; Hilsted LM; Sørensen E; Ostrowski SR; Harboe ZB; Perch M; Sørensen SS; Rasmussen A; Bundgaard H; Garred P; Iversen K; Nielsen SD
Front Immunol; 2022; 13():832501. PubMed ID: 35281023
[TBL] [Abstract][Full Text] [Related]
20. Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults.
Erice A; Varillas-Delgado D; Caballero C
Clin Microbiol Infect; 2022 Jan; 28(1):139.e1-139.e4. PubMed ID: 34508885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
